accux-qa
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
CMA Member Access
CMA Members please log in below using your CMAJ account.
If you don't remember your CMAJ login, click here to reset it.
If you don't have a CMAJ account and know your CMA membership number, click here to create an account. If you don't know your CMA membership number, contact the Member Service Centre via telephone at 888-855-2555 ext. 8004 (Canada & Continental US only); 613-731-8610 ext. 8004 or via email at memberservicecentre@cma.ca.
Log in using your username and password
Log in through your institution
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
In this issue
Article tools
Respond to this article
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
Jump to section
- Article
- Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a new class of low-density lipoprotein (LDL-C)–lowering medications
- PCSK9 inhibitors have been shown to improve cardiovascular outcomes
- PCSK9 inhibitors are recommended as add-on therapy in patients at very high risk
- PCSK9 inhibitors are well tolerated, but long-term safety data are lacking
- The price of PCSK9 inhibitors limits their cost-effectiveness
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.